PURPOSE: Repeat gamma knife stereotactic radiosurgery (GKRS) for recurrent or persistent trigeminal neuralgia induces an additional response but at the expense of an increased incidence of facial numbness. The present series summarized the results of a repeat treatment series at Wake Forest University Baptist Medical Center, including a multivariate analysis of the data to identify the prognostic factors for treatment success and toxicity. METHODS AND MATERIALS: Between January 1999 and December 2007, 37 patients underwent a second GKRS application because of treatment failure after a first GKRS treatment. The mean initial dose in the series was 87.3 Gy (range, 80-90). The mean retreatment dose was 84.4 Gy (range, 60-90). The dosimetric variables recorded included the dorsal root entry zone dose, pons surface dose, and dose to the distal nerve. RESULTS: Of the 37 patients, 81% achieved a >50% pain relief response to repeat GKRS, and 57% experienced some form of trigeminal dysfunction after repeat GKRS. Two patients (5%) experienced clinically significant toxicity: one with bothersome numbness and one with corneal dryness requiring tarsorraphy. A dorsal root entry zone dose at repeat treatment of >26.6 Gy predicted for treatment success (61% vs. 32%, p = .0716). A cumulative dorsal root entry zone dose of >84.3 Gy (72% vs. 44%, p = .091) and a cumulative pons surface dose of >108.5 Gy (78% vs. 44%, p = .018) predicted for post-GKRS numbness. The presence of any post-GKRS numbness predicted for a >50% decrease in pain intensity (100% vs. 60%, p = .0015). CONCLUSION: Repeat GKRS is a viable treatment option for recurrent trigeminal neuralgia, although the patient assumes a greater risk of nerve dysfunction to achieve maximal pain relief.
PURPOSE:Repeat gamma knife stereotactic radiosurgery (GKRS) for recurrent or persistent trigeminal neuralgia induces an additional response but at the expense of an increased incidence of facial numbness. The present series summarized the results of a repeat treatment series at Wake Forest University Baptist Medical Center, including a multivariate analysis of the data to identify the prognostic factors for treatment success and toxicity. METHODS AND MATERIALS: Between January 1999 and December 2007, 37 patients underwent a second GKRS application because of treatment failure after a first GKRS treatment. The mean initial dose in the series was 87.3 Gy (range, 80-90). The mean retreatment dose was 84.4 Gy (range, 60-90). The dosimetric variables recorded included the dorsal root entry zone dose, pons surface dose, and dose to the distal nerve. RESULTS: Of the 37 patients, 81% achieved a >50% pain relief response to repeat GKRS, and 57% experienced some form of trigeminal dysfunction after repeat GKRS. Two patients (5%) experienced clinically significant toxicity: one with bothersome numbness and one with corneal dryness requiring tarsorraphy. A dorsal root entry zone dose at repeat treatment of >26.6 Gy predicted for treatment success (61% vs. 32%, p = .0716). A cumulative dorsal root entry zone dose of >84.3 Gy (72% vs. 44%, p = .091) and a cumulative pons surface dose of >108.5 Gy (78% vs. 44%, p = .018) predicted for post-GKRS numbness. The presence of any post-GKRS numbness predicted for a >50% decrease in pain intensity (100% vs. 60%, p = .0015). CONCLUSION:Repeat GKRS is a viable treatment option for recurrent trigeminal neuralgia, although the patient assumes a greater risk of nerve dysfunction to achieve maximal pain relief.
Authors: Toshinori Hasegawa; Douglas Kondziolka; Richard Spiro; John C Flickinger; L Dade Lunsford Journal: Neurosurgery Date: 2002-03 Impact factor: 4.654
Authors: J Régis; P Metellus; H Dufour; P H Roche; X Muracciole; W Pellet; F Grisoli; J C Peragut Journal: J Neurosurg Date: 2001-08 Impact factor: 5.115
Authors: C L Rogers; A G Shetter; J A Fiedler; K A Smith; P P Han; B L Speiser Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-01 Impact factor: 7.038
Authors: Ahmed M Raslan; Reynaldo DeJesus; Caglar Berk; Andrew Zacest; Jim C Anderson; Kim J Burchiel Journal: J Neurosurg Date: 2009-10 Impact factor: 5.115
Authors: John T Lucas; Adrian M Nida; Scott Isom; Kopriva Marshall; John D Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-07 Impact factor: 7.038
Authors: Aldo Berti; George Ibars; Xiaodong Wu; Alex Sabo; Michelle Granville; Gail Suarez; James G Schwade; Robert E Jacobson Journal: Cureus Date: 2018-05-09
Authors: Corbin A Helis; Emory McTyre; Michael T Munley; J Daniel Bourland; John T Lucas; Christina K Cramer; Stephen B Tatter; Adrian W Laxton; Michael D Chan Journal: Neurosurgery Date: 2019-11-01 Impact factor: 4.654
Authors: Guy C Jones; Ameer L Elaimy; John J Demakas; Hansi Jiang; Wayne T Lamoreaux; Robert K Fairbanks; Alexander R Mackay; Barton S Cooke; Christopher M Lee Journal: Case Rep Med Date: 2011-09-04
Authors: Ameer L Elaimy; Peter W Hanson; Wayne T Lamoreaux; Alexander R Mackay; John J Demakas; Robert K Fairbanks; Barton S Cooke; Sudheer R Thumma; Christopher M Lee Journal: Int J Otolaryngol Date: 2011-10-25